Zoekresultaten - You searched for Pharma

491 results

Mithra announces belux agreement with ceres pharma worth over eur 40 million

Read more

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Read more

Acacia Pharma announces its intention to launch an initial global offering and to list its shares on Euronext Brussels

Read more

Update on mithra and mayne pharma’s vaginal contraceptive ring opportunity

Read more

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Mithra Signs Exclusive License And Supply Agreement For The Commercialization Of Myring™ In Chile With Laboratorio Pasteur

Read more

ProPharma Group Announces the Acquisition of The Weinberg Group

Read more

FAIRplus: new project to improve data sharing and reuse in life sciences research

Read more

ProPharma Group Announces the Acquisition of Southwood Research

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

Ecosynth moves to new laboratories

Read more

Dosing of First Patient with investigational agent OMO-1

Read more

Pharmacokinetics in Drug Development - 2017

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

Read more

PharmaFluidics raises 7.3 million euro to expand commercialization of novel micro-chip device for biomarker, diagnostics and drug development applications

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

Ardena acquires ChemConnection adding API expertise

Read more

Ardena acquires Syntagon and strengthens API offering

Read more

Imec Presents Novel Organ-on-Chip Platform for Drug Screening

Read more

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients

Read more

OCTIMET has determined proof of target engagement in patient tumour tissue and a recommended phase II dose with OMO-1

Read more

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

Read more

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

Read more

Data Transparency in Pharma R&D - Update on Policy 70 and first practical experiences

Read more

Bio€quity Europe 2017

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

Mithra to Initiate PK Study for Estelle®

Read more

Mithra & Gynial sign commercialization agreement for MyringTM in Austria

Read more

QBD Webinar on validation of mobile apps

Read more

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

ThromboGenics Business Update - H1 2017

Read more

TiGenix strengthens US operations with senior appointments

Read more

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

BIO-Europe Spring® 2018

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

ThromboGenics Business Update - Q3 2017

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

ThromboGenics Strengthens Leadership Team

Read more

Life Sciences Baltics 2018

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

Mindbytes initiates oncology R&D program focused on patient empowerment and is selected as one of five finalists for Astellas Oncology C3 Prize®

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

BIO Asia International Conference

Read more

ChinaBio Partnering Forum 2018

Read more

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Read more

Mithra and Adamed Sign Commercialization Agreement for MyringTM in the Czech Republic

Read more

Ablynx strongly believes unsolicited conditional proposal from Novo Nordisk fundamentally undervalues the company and its future prospects

Read more

Ablynx announces board changes

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

Ablynx announces 2017 full year results

Read more

Rousselot innovation days 2018

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Mithra announces injectable contract with Midas Pharma

Read more

CMAST: New partnership launched to facilitate the development of new drugs for children across Europe

Read more

CMAST to participate in the bio international convention (Boston, us - 4-7 june, 2018)

Read more

Mithra signs binding heads of terms for commercialization of Estelle® in South Korea with women's health specialist Hyundai Pharm

Read more

ThromboGenics Plans Name Change to "Oxurion"

Read more

BIO-Europe Spring® 2019 - Where the global biotech industry comes to partner

Read more

ONTOFORCE and ChemAxon facilitate linked chemical data search

Read more

Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors

Read more

Mithra signs exclusive license and supply agreement with Adcock Ingram for commercialization of Estelle® in Southern Africa

Read more

Mithra signs exclusive license and supply agreement for vaginal contraceptive ring in Australia and New Zealand

Read more

New project launched to harmonize Clinical Data and develop a 21st Century Ecosystem for Real World Health Research in Europe

Read more

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

Read more

ChinaBio Partnering Forum 2019

Read more

Terrific year for Belgian biotech companies

Read more

Wanted: 18,200 highly skilled profiles for bottleneck sectors

Read more

Brain imaging AI leader icometrix raises $18 million in new funding

Read more

JLABS Info Session Webinar

Read more

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

Read more

Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Flanders Vaccine: A catalyst for public-private partnerships in vaccine related research and business

Read more

TiGenix reports 2016 full year results

Read more

Scientists expose protein responsible for allergic diseases

Read more

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Read more

RegMed

Read more

Flanders @ BIOJapan 2017: Flemish Life Sciences & Biotech Week

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

ThromboGenics Business Update - Q1 2017

Read more

Market of 105 billion euros open to Flemish biotech companies

Read more

Mithra Receives GMP Approval for Myring™ Production

Read more

Biocartis Group NV: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Read more

Smart Implant & (Bio-)medical Imaging Platform Meeting

Read more

Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer

Read more

Ablynx appoints Markus Ewert as Chief Business Officer

Read more

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Read more

European Business Development Conference

Read more

Symposium on Liquid Biopsies & Cancer

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Read more

flanders.bio strenghtens its team with the appointment of 3 Programme Managers

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Read more

MDxHealth Prepares for Growth with Executive Team Expansion

Read more

Biocartis announces H1 2017 results

Read more

PharmaFluidics appoints Fasha Mahjoor as independent director

Read more

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Read more

Flanders @ BIO International Convention 2018

Read more

Advipro (Lille+Willebroek) scoort met Europese scoop voor farmasector en investeert in uniek trainingscenter met operationele cleanroom

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

ABL acquisition extends Ardena’s early-phase offering

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

The Adecco Group Announces the Acquisition of CMAST

Read more

Mithra Announces Valorization of French Subsidiary

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Read more

Galapagos to enter NASDAQ Biotech Index

Read more

New at Poulpharm: Animal facility for studies demanding high-containment levels

Read more

Confo Therapeutics enters into drug discovery collaboration with Roche

Read more

Galapagos - Update on progress in cystic fibrosis programs

Read more

Galapagos - Positive topline results with GLPG1972 in osteoarthritis patients

Read more

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman

Read more

MDxHealth financial results

Read more

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

Biocartis Establishes R&D Center in the US

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

CMAST to participate in the bio-europe spring partnering conference

Read more

European Business Development Conference 2018

Read more

Flanders @ BIOJapan 2018: Flemish Life Sciences & Biotech Week

Read more

Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies

Read more

VIB: Molecular details of protein crystal nucleation uncovered

Read more

Promethera Biosciences Announces Updates to its Board of Directors

Read more

MDxHealth Provides First Quarter 2018 Business Update

Read more

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Read more

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Read more

Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

Human Biotech & Animal Health Business Partnering Summit

Read more

Bone Therapeutics Business Update for First Quarter 2018

Read more

Flanders.bio appoints new management team to step up its strategy

Read more

CMAST presents new website and look & feel at Europe’s 2nd largest life sciences conference

Read more

Biocartis: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

TiGenix announces a change in its Board of Directors and its Management Team

Read more

Biogazelle appoints Armin Winands as new CEO

Read more

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Read more

Xendo and its affiliate, Sofus Regulatory Affairs AB have been acquired by ProPharma Group

Read more

argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Read more

Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China

Read more

Ardena expands nanomedicine capabilities

Read more

De chemie is goed voor België (en omgekeerd)

Read more

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

Read more

Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

Read more

PharmaFluidics Facilitates Ultra-high-resolution Proteomics Analysis Through Agreement with Thermo Fisher Scientific

Read more

Mithra: 2018 update and 2019 outlook given at the cphi conference

Read more

Internationalisation

Read more

Galapagos: Topline interim results of FALCON trial Part 1 in CF

Read more

Het succes van de Vlaamse biotechsector duwt de groei van gespecialiseerde toeleveranciers spectaculair de hoogte in.

Read more

ProDigest has been nominated for the Deloitte Technology Fast 50

Read more

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Read more

3e Job Tasting Advipro

Read more

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Read more

BioTrinity 2019

Read more

Inbiose secures €4 million in debt financing

Read more

Flanders @ BIO International Convention 2019

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Read more

Start2pharma 2-days: CGMP & QMS for professionals with 0 – 2 years’ experience in the industry

Read more

FDA Approves OCTIMET’s Investigational New Drug Application to evaluate OMO-1 in patients

Read more

Pharmafluidics’ new product launch steers ‘on-a-chip’ separations of complex biological samples to new heights

Read more

Mithra Strengthens Management Team With Key Appointments

Read more

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

Read more

Oxurion NV Business Update - FY 2018

Read more

GSK meets Belgian universities: Regional scientific associations bring together researchers from industry and universities

Read more

3e Job Tasting Day Advipro

Read more

Mithra announces new agreement with GSP for development of an additional injectable

Read more

Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

Read more

New social, ethical & economic impact studies and activities developed by Sanquin

Read more

Preventing cell death as novel therapeutic strategy for rheumatoid arthritis

Read more

OCTIMET Oncology announces the appointment of Shelley Margetson as CEO

Read more

argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

Read more

The future of healthcare is digital

Read more

eTheRNA: Appointment of Chief Financial Officer

Read more

Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies

Read more

Effective & Business Value-Oriented Patents

Read more

VIB-KU Leuven: Duvel Moortgat opens scientific pilot brewery and presents BSSH Awards to Sir Paul Nurse, 2001 Nobel Laureate

Read more

Flanders @ BioJapan 2019: Flemish Life Sciences & Biotech Week

Read more

European Business Development Conference 2019

Read more

BioFIT 2019

Read more

Development of a new leishmaniasis drug wins EU funding

Read more

VIB: Using ketone bodies in the fight against lymphedema

Read more

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

Read more

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

CMAST is stepping into a strategic partnership with FlandersBio

Read more

TiGenix to participate in key investor conferences in April 2017

Read more

knowledge for growth 2017

Read more

Flanders @ BIO International Convention 2017

Read more

EARLY PHASE DRUG DEVELOPMENT COURSE - FUTURE MEANS CREATIVITY

Read more

Life sciences remuneration seminar

Read more

Nordic Life Science Days 2017

Read more

Bootcamp in Entrepreneurial Innovation in Orphan Diseases

Read more

Ablynx announces warrant exercise

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

BioPharm America™ 2017 - 10th Annual International Partnering Conference

Read more

BioTrinity 2017 - Europe's Leading Biopartnering and Investment Conference

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Read more

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Read more

FairJourney Biologics announces an innovative technology to discover antibody molecules in full therapeutic format

Read more

TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas

Read more

Ablynx to present at upcoming USA Investor Conferences

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

Overnight skin care

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

Flanders @ BIO-Europe 2017

Read more

TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

TiGenix Launches Global Phase III Trial for Cx601

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Daily Newsflash- 14/06/17

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

flanders.bio's flagship event knowledge for growth 2018

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Expertise

Read more

Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

TiGenix opens US headquarters in Cambridge, MA

Read more

Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Read more

Industrial automation companies from Baden-Württemberg looking for collaborations

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

TiGenix: Transparency Information

Read more

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Read more

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Mindbytes expands to North America to develop next generation serious medical games driven by artificial intelligence

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

Ablynx to present at upcoming investor conferences in London

Read more

flanders.bio - CMAST Partner Day: Realizing Life Science Innovation with Impact

Read more

Ablynx Announces Warrant Exercise

Read more

Bio€quity Europe 2018

Read more

flanders.bio - Janssen Pharma Partner Day 2018: Innovate – Connect – Collaborate!

Read more

pi life sciences consultancy launches Music For Life-campaign to lift the taboo on young dementia

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

TiGenix to participate and present at key investor and business development meetings

Read more

BioFIT 2017

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Ablynx files registration statement for a proposed global offering

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

Ablynx - Publication in accordance with art.14 of the Belgian law of 2/05/2017 regarding the publication of major shareholdings (the "transparancy law")

Read more

Seminar: How Real World Data will change your clinical development to the better

Read more

QM Conference: Partnerships in Quality Management

Read more

Best practices in Aseptic Processing Challenges, Solutions and site visits

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

Networking

Read more

Ablynx announces launch of proposed global offering

Read more

Bridging Preclinical and Clinical Development

Read more

BioTrinity 2018

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

GAMIAN-Europe & CMAST announce collaborative partnership

Read more

Suspension of trading in Ablynx shares on Euronext Brussels

Read more

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Read more

Bio€quity is coming to Ghent - Make your mark!

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Read more

Mithra Completes Recruitment for Estelle® Phase III Study in US and Canada

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

TiGenix announces partial conversion of bonds

Read more

Press Release - Life Sciences & Biotechnology

Read more

Ablynx - Correction of Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Ablynx to present at upcoming investor conferences in London and Paris

Read more

Ablynx: publication regarding the publication of major shareholdings

Read more

For the second year in a row ProDigest wins the Life Science Technology Award in the Deloitte Technology Fast 50 Competition

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Read more

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Read more

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Read more

BIO INTERNATIONAL CONVENTION 2018

Read more

Ablynx - Publication in accordance with §14 of the Belgian Law

Read more

Ablynx to host webcast about Phase III Hercules Study

Read more

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

Read more

BioFIT 2018

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

Daily Newsflash - 13/12/2017

Read more

Nordic Life Science Days 2018

Read more

Mithra Announces Injectables Agreement with GSP

Read more

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

Ablynx - notice in relation to waiver of lock-up restriction

Read more

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

Ablynx to present at the 36th annual J.P. Morgen Healthcare conference

Read more

Takeda announces its intention to acquire TiGenix

Read more

Imec’s SWEET study Collects World’s Largest Dataset on Stress Detection

Read more

TiGenix - Transparency Information

Read more

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

Daily Newsflash - 16/01/2017

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

Service - 20/02/2018

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Read more

MDxHealth contract SelectMDx with Roman Hospital

Read more

CMAST supports Rejuvenate Biomed in their search for ways to impact the ageing process

Read more

Sell Your Science: Best Practices for Developing an Effective Non-Confidential Pitch Deck

Read more

MITHRA and ALVOGEN sign LSA for vaginal contraception ring in Russia

Read more

Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Accepted for Filing by FDA

Read more

VLAIO kent QbD subsidie toe voor innovatie in celtherapie procesontwikkeling

Read more

Networking - 14/06/2018

Read more

DuPont and Inbiose Celebrate EU Regulatory Approval of Their First Human Milk Oligosaccharide Ingredient for Infant Formula

Read more

Previously announced tender offers by Sanofi to acquire Ablynx will commence on april 4, 2018

Read more

CMAST to present at a Veeva seminar on modernizing quality management / April 10th, 2018 / Paris, France

Read more

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Ablynx teams up with AIM for the design and implementation of its commercial supply chain for caplacizumab

Read more

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Read more

Daily newsflash - 04/04/2018

Read more

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data

Read more

Ablynx publication in accordance with article 14 of the belgian law of 2 may 2007

Read more

Flanders @ BIO-Europe 2018

Read more

ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Ablynx announces Warrant Exercise

Read more

Mithra Announces Last Subject Visit in Estelle® Phase III Study in EU/Russia and Completion of Endometrial Substudy

Read more

Daily newsflash - 03/05/2018

Read more

ThromboGenics Business Update - Q1 2018

Read more

Sanofi and Ablynx announce the successful results of the initial tender offer period for ablynx and commencement of squeeze-out tender period

Read more

Press Release - Life Sciences & Biotechnology - 15/05/2018

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

ProDigest: PROMISE

Read more

ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

Read more

Press Release - Life Sciences & Biotechnology - 23/05/2018

Read more

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149

Read more

Ablynx: Notice In Relation To The Convertible Bonds Due May 2020

Read more

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Read more

Sanofi complets its acquisition of Ablynx following the expiration of the squeeze-out procedure

Read more

CMAST attends the 2nd General Assembly of RESCEU; a European project focusing on the battle against RSV (June 21st-22nd, Oxford - UK)

Read more

argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

Read more

Daily newsflash - 20/06/2018

Read more

SCK•CEN seminar to discover the latest innovations in nuclear medicine

Read more

CMAST: Horizon Europe – looking at the future or building on the past?

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

International Conference on Industrial Biotechnology and Bioprocessing

Read more

ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study

Read more

Mithra announces positive top-line results of estelle® phase III oral contraceptive study in eu/russia

Read more

Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging

Read more

Press Release - Life Sciences & Biotechnology - 10/08/2018

Read more

Start with the end in Mind – Healthcare Market Access in the Digital Age

Read more

Daily newsflash - 28/08/2018

Read more

Communicating Toxicology: What’s the Risk ?

Read more

ThromboGenics becomes "Oxurion"

Read more

ThromboGenics Business Update - H1 2018

Read more

Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Website

Read more

Patiëntenparticipatie doorheen de ontwikkelingscyclus van een geneesmiddel

Read more

V-Bio Ventures participates in 22.5 million euros series B financing round of HORAMA

Read more

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)

Read more

Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of DME

Read more

Mithra Finalizes Contract for the Commercialization of Estelle® with South Korean Women's Health Leader Hyundai Pharm

Read more

flanders.bio's flagship event knowledge for growth 2019

Read more

Belgium-Korea Pharma-Bio Conference

Read more

Daily Newsflash - 15/10/2018

Read more

Oxurion NV Business Update - Q3 2018

Read more

Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project

Read more

Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting

Read more

Press Release - Life Sciences & Biotechnologie - 26/10/2018

Read more

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

SWAT4(HC)LS 2018

Read more

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Read more

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle®

Read more

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Read more

Educational Workshop with PK-Sim® & MoBi® about PBPK Modeling & Simulation for Human Dose Projection and DDI Prediction

Read more

Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

Read more

JLABS @ BE Info Session (webinar)

Read more

BIO INTERNATIONAL CONVENTION 2019

Read more

ECCRT Data Transparency Conference

Read more

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

reMYND raises 12 million EUR to assess clinical proof-ofmechanism in Alzheimer’s and to expand into orphan disorders

Read more

UNDER EMBARGO UNTIL 1 AM CET, DECEMBER 18th, 2018

Read more

BioPharm America™ 2018

Read more

Confo Therapeutics sluit exclusieve, wereldwijde licentie met VIB voor gebruik van nieuwe, baanbrekende technologie

Read more

IQVIA, QbD and Select enter into a strategic partnership with flanders.bio as of January 1st, 2019

Read more

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

Read more

Inari Broadens Research Footprint With Expansion to Belgian Life Sciences Hub

Read more

Evotec and Galapagos enter into collaboration in the field of fibrosis

Read more

Daily Newsflash - 26/02/2019

Read more

The European Bank for induced pluripotent Stem Cells launches a second project phase

Read more

The Innovative Medicines Initiative launches a public-private coordination and support action

Read more

V-Bio Ventures leads AgomAb Therapeutics’ 21m EUR series A financing round

Read more

Regional scientific associations bring together researchers from industry and universities

Read more

Workshop: Blockchain in Clinical Trials

Read more

ActoBio Therapeutics™’ CTO Lothar Steidler Elected VIB Alumni Awardee 2019

Read more

Mindbytes bvba publishes first peer-reviewed manuscript on its serestm methodological framework and demonstrates proof-of-concept

Read more

Confo Therapeutics raises €30 million in Series A financing

Read more

Invitation: Science for health (11/09/2019, Square Brussels)

Read more

Science for Health 2019

Read more

ViroVet and Pirbright join forces to develop African swine fever antivirals

Read more

eTheRNA: Linking clinical cure of metastatic melanoma with immune responses in the TriMix DC-MEL IPI study.

Read more

How to Hold Your First-In-Human Trial?

Read more

Immunity for Health

Read more

Daily Newsflash - 20/06/2019

Read more

Flanders @ Bio-Europe 2019

Read more

Reminder: Science for health (11/09/2019, Square Brussels)

Read more

Nordic Life Science Days 2019

Read more

BioPharm America™ 2019

Read more

Press Release

Read more

Helis Academy Patient Centricity in Clinical Trials

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Read more

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma

Read more

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

Read more

Kinesis Pharma fully integrated & operative under Venn Life Science Brand

Read more

ALTIUS Pharma & Life Sciences seminar

Read more

Mithra announces Myring™ update

Read more

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Read more

OPINNO educational module: What does it take to work in a life sciences company?

Read more

BCF Career Event - Ghent

Read more

BioVox stelt white paper over kankerimmunotherapie voor: zal het kanker genezen?

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

Mithra Submits Myring™ for European Marketing Approval

Read more

Mithra announces 2017 half year results

Read more

Mithra Announces Positive Outcome of Myring™ Commercial Batch Bioequivalence Study

Read more

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Read more

Biotech & Healthcare Conference - New York, US

Read more

Networking - 01/03/2018

Read more

Celyad obtains additional US patent for cancer treatment

Read more

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

Read more

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East

Read more

Thank you for attending the latest flanders.bio-Janssen Partner Day

Read more

Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe

Read more

Daily Newsflash - 06/03/2018

Read more

argenx announces results of Annual General Meeting 2017

Read more

Daily Newsflash - 27/02/2018

Read more

OPINNO BioBizz Café ICC Ghent

Read more

Daily Newsflash- 29/08/2017

Read more

Daily Newsflash - 2/03/2018

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

argenx reports third quarter 2017 financial results and provides business update

Read more

Mithra Announces 2018 Half Year Results

Read more

Mithra announces complex therapeutics update

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

Daily Newsflash - 02/03/2018

Read more

Daily newsflash - 19/10/2018

Read more

Do you have to become officially a BIOBANK under the new Belgian law?

Read more

Daily Newsflash- 7/07/2017

Read more

Daily Newsflash - 1/02/2018

Read more

Daily newsflash - 13/03/2018

Read more

Trainings - EDUCATE

Read more

START2PHARMA: VALIDATION FUNDAMENTALS: EQUIPMENT & SYSTEM QUALIFICATION

Read more

Daily Newsflash- 28/09/2017

Read more

Daily Newsflash - 6/02/2018

Read more

Daily newsflash - 30/08/2018

Read more

Daily Newsflash - 20/02/2019

Read more

Daily Newsflash - 25/03/2019

Read more

Daily Newsflash - 17/05/2019

Read more

Services

Read more

Follow-up info flanders.bio-CMAST Partner Day

Read more

7/12/2017

Read more

BCF Career Event

Read more

flanders.bio - Roche Diagnostics Partner Day 2018: ’Towards high-quality Cell Therapy’

Read more

The right funding at the right time: how to make the right call?

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

Daily Newsflash- 26/09/2017

Read more

Dirk Reyn has been appointed as chairman of the Board of Directors of flanders.bio

Read more

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

Read more

Mithra signs principle agreement for commercialization of Estelle® in canada

Read more

Membership Information

Read more

Dirk Reyn benoemd als voorzitter van de Raad van Bestuur van flanders.bio

Read more